Your browser is no longer supported. Please, upgrade your browser.
CYTK Cytokinetics, Incorporated daily Stock Chart
CYTK [NASD]
Cytokinetics, Incorporated
Index- P/E- EPS (ttm)-2.12 Insider Own1.30% Shs Outstand59.91M Perf Week1.79%
Market Cap716.52M Forward P/E- EPS next Y-2.07 Insider Trans-49.32% Shs Float51.83M Perf Month-21.11%
Income-121.70M PEG- EPS next Q-0.50 Inst Own96.10% Short Float16.09% Perf Quarter10.43%
Sales26.90M P/S26.64 EPS this Y-8.20% Inst Trans-0.05% Short Ratio9.09 Perf Half Y3.37%
Book/sh-0.18 P/B- EPS next Y2.40% ROA-55.70% Target Price20.83 Perf Year42.55%
Cash/sh3.76 P/C3.18 EPS next 5Y15.00% ROE- 52W Range7.72 - 16.96 Perf YTD12.72%
Dividend- P/FCF- EPS past 5Y-38.80% ROI-83.50% 52W High-29.48% Beta1.17
Dividend %- Quick Ratio9.00 Sales past 5Y-10.60% Gross Margin- 52W Low54.82% ATR1.45
Employees156 Current Ratio9.00 Sales Q/Q-44.70% Oper. Margin- RSI (14)50.48 Volatility11.14% 14.48%
OptionableYes Debt/Eq- EPS Q/Q-7.00% Profit Margin- Rel Volume0.71 Prev Close12.05
ShortableYes LT Debt/Eq- EarningsMar 03 AMC Payout- Avg Volume918.11K Price11.96
Recom2.20 SMA206.78% SMA50-7.82% SMA2001.22% Volume653,092 Change-0.75%
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-10-18Resumed Morgan Stanley Equal-Weight $10
Nov-22-17Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17Reiterated H.C. Wainwright Buy $26 → $17
Jul-31-17Initiated Morgan Stanley Overweight $24
Mar-08-17Initiated Rodman & Renshaw Buy $25
Feb-06-17Upgrade Needham Buy → Strong Buy $17 → $22
Dec-16-16Initiated Cantor Fitzgerald Overweight $21
Jul-28-16Reiterated Needham Buy $15 → $17
Nov-10-15Reiterated FBR Capital Outperform $14 → $24
Nov-09-15Reiterated ROTH Capital Buy $18 → $22
Jul-24-15Reiterated MLV & Co Buy $9 → $14
Dec-31-14Reiterated ROTH Capital Buy $13 → $18
Nov-04-14Upgrade MLV & Co Hold → Buy $9
Apr-28-14Reiterated Needham Buy $25 → $15
Apr-25-14Downgrade MLV & Co Buy → Hold $26 → $5
Jun-26-13Reiterated MLV & Co Buy $24 → $26
Jul-02-12Initiated Needham Buy $2.50
Oct-13-11Initiated Rodman & Renshaw Mkt Outperform $4
Apr-01-20 07:32AM  Edited Transcript of CYTK earnings conference call or presentation 3-Mar-20 9:30pm GMT Thomson Reuters StreetEvents -5.43%
Mar-30-20 01:35PM  Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual GlobeNewswire +8.85%
07:30AM  Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual GlobeNewswire
Mar-20-20 04:00PM  CYTOKINETICS TO ANNOUNCE BASELINE CHARACTERISTICS FROM GALACTIC-HF DURING ACC.20/WCC GlobeNewswire +6.11%
Mar-04-20 07:30AM  Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis GlobeNewswire
Mar-03-20 05:15PM  Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:00PM  Cytokinetics Reports Fourth Quarter 2019 Financial Results GlobeNewswire
07:30AM  Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure GlobeNewswire
Feb-28-20 07:30AM  Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day GlobeNewswire
Feb-26-20 08:30AM  Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis GlobeNewswire
08:30AM  Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis PR Newswire
Feb-25-20 12:30PM  Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-20-20 07:30AM  Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting GlobeNewswire
Feb-18-20 04:00PM  Cytokinetics to Announce Fourth Quarter Results on March 3, 2020 GlobeNewswire +9.76%
Feb-13-20 12:31PM  Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-12-20 10:55AM  Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks Zacks
Feb-06-20 04:30AM  Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure GlobeNewswire
Jan-30-20 06:59AM  Cytokinetics, Incorporated (NASDAQ:CYTK): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Jan-22-20 07:30AM  Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants GlobeNewswire
Jan-17-20 09:26AM  Implied Volatility Surging for Cytokinetics (CYTK) Stock Options Zacks
Jan-13-20 07:30AM  Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones GlobeNewswire +8.03%
Jan-10-20 08:10PM  Wall Street Views on American Water Works, Royal Caribbean and Others Barrons.com
Jan-06-20 07:30AM  Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274 GlobeNewswire
Jan-03-20 05:43PM  2020 Preview: The year ahead in Bay Area biotech and health American City Business Journals
Dec-18-19 07:30AM  Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis GlobeNewswire
Dec-10-19 10:45AM  Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy? Insider Monkey
Dec-09-19 10:03AM  World's largest biotech company to move up to BioMed's big South City project American City Business Journals
Dec-05-19 07:30AM  Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND GlobeNewswire
Nov-27-19 04:00PM  Cytokinetics to Participate in the Piper Jaffray Healthcare Conference GlobeNewswire
09:45AM  5 Strong Buy Biotech Stocks With More Than 80% Upside InvestorPlace
Nov-26-19 04:00PM  Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND GlobeNewswire
Nov-18-19 09:00AM  New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function PR Newswire
09:00AM  New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function GlobeNewswire
Nov-11-19 12:14PM  Edited Transcript of CYTK earnings conference call or presentation 31-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
09:00AM  Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2019 GlobeNewswire
Nov-08-19 07:30AM  Cytokinetics Announces Pricing of Public Offering of Convertible Senior Notes GlobeNewswire
Nov-06-19 04:05PM  Cytokinetics Announces Proposed Public Offering of Convertible Senior Notes GlobeNewswire
Nov-05-19 07:30AM  Cytokinetics to Participate in the Credit Suisse 28th Annual Healthcare Conference GlobeNewswire
Nov-01-19 11:08AM  Here is What Hedge Funds Really Think About Cytokinetics, Incorporated (CYTK) Insider Monkey
Oct-31-19 05:15PM  Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:00PM  Cytokinetics Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-24-19 04:00PM  Cytokinetics to Announce Third Quarter Results on October 31, 2019 GlobeNewswire
Oct-17-19 10:30AM  Should You Worry About Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Pay? Simply Wall St.
Oct-04-19 07:30AM  Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting Globenewswire Test
07:30AM  Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting GlobeNewswire
Oct-01-19 12:10PM  Edited Transcript of CYTK earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-26-19 04:00PM  Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire -10.08%
04:00PM  Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting GlobeNewswire
Sep-25-19 07:30AM  Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals GlobeNewswire
Sep-23-19 05:54AM  3 Biotech Stocks Surging on Positive Results TipRanks
Sep-16-19 07:30AM  Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23 Annual Scientific Meeting GlobeNewswire
Sep-06-19 04:00PM  Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting GlobeNewswire
Sep-03-19 04:00PM  Cytokinetics to Present at September Investor Conferences GlobeNewswire
Sep-02-19 01:00PM  Is Cytokinetics (NASDAQ:CYTK) Using Too Much Debt? Simply Wall St.
Aug-27-19 07:30AM  Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA GlobeNewswire
Aug-09-19 01:23AM  Cytokinetics Inc (CYTK) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 08:30PM  Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:06PM  Cytokinetics Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-01-19 10:33AM  Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-31-19 07:30AM  Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Associations Basic Cardiovascular Sciences Scientific Sessions GlobeNewswire
Jul-29-19 10:08AM  Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets and more American City Business Journals
Jul-26-19 09:56AM  Does Cytokinetics, Incorporated (NASDAQ:CYTK) Have A Volatile Share Price? Simply Wall St.
Jul-25-19 04:28PM  First big lease lands at Kilroy's huge Oyster Point project American City Business Journals
04:00PM  Cytokinetics to Announce Second Quarter Results on August 8, 2019 GlobeNewswire
Jul-24-19 07:30AM  Cytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics GlobeNewswire
Jul-23-19 07:30AM  Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy GlobeNewswire
Jul-22-19 04:00PM  Cytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Associations Basic Cardiovascular Sciences Scientific Sessions GlobeNewswire
Jul-18-19 10:33AM  Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-15-19 07:30AM  Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure GlobeNewswire
Jun-28-19 07:30AM  Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference GlobeNewswire
Jun-27-19 01:29PM  Did Hedge Funds Drop The Ball On Cytokinetics, Inc. (CYTK) ? Insider Monkey
Jun-24-19 04:00PM  Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference GlobeNewswire
Jun-13-19 02:40PM  Could The Cytokinetics, Incorporated (NASDAQ:CYTK) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jun-12-19 04:00PM  Cytokinetics to Present at the JMP Securities Life Sciences Conference GlobeNewswire
09:24AM  Edited Transcript of CYTK earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-30-19 07:30AM  Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS GlobeNewswire
May-09-19 08:24PM  Cytokinetics Inc (CYTK) Q1 2019 Earnings Call Transcript Motley Fool
06:05PM  Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:54PM  Cytokinetics: 1Q Earnings Snapshot Associated Press
04:00PM  Cytokinetics Reports First Quarter 2019 Financial Results GlobeNewswire
May-08-19 04:00PM  Cytokinetics to Hold Annual Meeting of Stockholders GlobeNewswire
May-06-19 10:29AM  Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters American City Business Journals +7.12%
09:18AM  Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints MarketWatch
May-05-19 01:11PM  Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting GlobeNewswire
May-02-19 10:32AM  Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-25-19 04:00PM  Cytokinetics to Announce First Quarter Results on May 9, 2019 GlobeNewswire
01:47PM  What Are Analysts Expecting From Cytokinetics, Incorporated (NASDAQ:CYTK) In The Next Couple Of Years? Simply Wall St.
Apr-18-19 10:33AM  Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know Zacks
Apr-01-19 04:00PM  Cytokinetics to Present at April Investor Conferences GlobeNewswire
07:00AM  New Research Coverage Highlights International Paper, Square, Sealed Air, Calix, e.l.f. Beauty, and Cytokinetics Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-27-19 10:55AM  Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks
Mar-21-19 07:51AM  The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering Benzinga -13.25%
Mar-20-19 04:51PM  Here's Why Cytokinetics Stock Jumped Today Motley Fool +19.04%
08:30AM  Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis PR Newswire
08:30AM  Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis GlobeNewswire
Mar-18-19 04:00PM  Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19 GlobeNewswire +5.65%
Mar-11-19 04:04PM  Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19 GlobeNewswire +5.60%
11:23AM  Edited Transcript of CYTK earnings conference call or presentation 21-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-19 04:10PM  Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting GlobeNewswire
10:38AM  Some Cytokinetics Shareholders Are Down 43% Simply Wall St.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GAGE L PATRICKDirectorMar 06Sale14.828,000118,59220,000Mar 20 03:21 PM
BVF PARTNERS L P/IL10% OwnerFeb 13Sale15.791,072,03016,923,923424,419Feb 18 06:00 PM
Blum Robert IPresident & CEOJan 15Sale12.964,95064,159224,107Jan 16 04:53 PM
Blum Robert IPresident & CEODec 16Sale10.226,00061,326229,057Dec 17 04:24 PM
BVF PARTNERS L P/IL10% OwnerDec 11Buy9.52118,4131,126,7003,617,776Dec 12 07:49 PM
BVF PARTNERS L P/IL10% OwnerDec 10Buy9.40223,6592,102,3953,557,673Dec 12 07:49 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 05Sale9.801,50014,700121,350Dec 06 04:42 PM
HENDERSON JOHN TDirectorNov 19Buy8.576,00051,4276,250Jan 02 02:22 PM
Blum Robert IPresident & CEONov 15Sale8.086,00048,508235,057Nov 18 04:12 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 07Sale9.981,50014,970122,850Nov 08 05:08 PM
Blum Robert IPresident & CEOOct 15Sale11.166,00066,975238,022Oct 16 05:42 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 03Sale11.221,50016,830122,067Oct 04 05:13 PM
Blum Robert IPresident & CEOSep 16Sale12.746,00076,469244,022Sep 17 05:08 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 05Sale13.691,50020,531123,567Sep 06 04:48 PM
Blum Robert IPresident & CEOAug 15Sale12.646,00075,815250,022Aug 16 05:45 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 08Sale13.521,50020,280125,067Aug 09 05:07 PM
Blum Robert IPresident & CEOJul 15Sale10.946,00065,632256,022Jul 16 05:25 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 11Sale11.261,50016,890126,567Jul 12 07:41 PM
Blum Robert IPresident & CEOJun 17Sale9.716,00058,238262,022Jun 19 04:52 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 06Sale10.311,50015,463128,067Jun 07 05:37 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 02Sale8.291,50012,430129,567May 03 05:34 PM